Ask Warren

Cytogen

217330 · KOSDAQ · ₩217330 · 싸이토젠

₩2,315▼ ₩30 (1.28%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩6.8B₩6.4B₩6.5B₩7.6B₩6.3B₩5.6B₩5.6B₩3.3B
Cost of sales₩4.8B₩4.5B₩5.5B₩6B₩4.8B₩4.2B₩4B₩2.3B
Gross profit₩2.1B₩1.9B₩1.1B₩1.6B₩1.5B₩1.4B₩1.6B₩1.1B
Operating income−₩1.2B−₩1.5B−₩2.6B−₩1.3B−₩1.9B−₩2.4B−₩1.9B−₩2.2B
Net income−₩2.2B−₩1.3B−₩5.5B−₩1.6B−₩2.8B−₩2.4B−₩8.3B−₩2.9B
Net income to shareholders−₩2.2B−₩1.3B−₩5.5B−₩1.6B−₩2.8B−₩2.4B−₩8.3B−₩2.9B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩55B₩57B₩62B₩68B₩68B₩72B₩72B₩84B
Current assets₩34B₩38B₩43B₩43B₩44B₩46B₩48B₩51B
Cash and equivalents₩15B₩13B₩11B₩6.4B₩18B₩39B₩31B₩29B
Total liabilities₩21B₩23B₩26B₩26B₩25B₩25B₩24B₩26B
Current liabilities₩4.5B₩11B₩15B₩14B₩13B₩14B₩4.7B₩4.5B
Borrowings₩13B₩14B₩15B₩15B₩14B₩14B₩14B₩13B
Total equity₩34B₩34B₩36B₩42B₩43B₩47B₩49B₩59B
Shareholders' equity₩33B₩34B₩36B₩41B₩43B₩46B₩49B₩58B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩150M−₩2.7B−₩2.1B−₩940M−₩1.9B−₩2B−₩2.3B−₩2.3B
Capital spending₩1.2B₩1.8M₩53M₩483M₩1.4B₩47M₩278M₩245M
Free cash flow−₩1.1B−₩2.7B−₩2.2B−₩1.4B−₩3.3B−₩2B−₩2.6B−₩2.6B

Consolidated where available. Amounts in won.

Also known as: Cytogen / 싸이토젠 / 217330 / KRX:217330

Source: KRX statistical information